Login / Signup
HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5).
Yoshiya Horimoto
Hiroko Onagi
Junichiro Watanabe
Takuo Hayashi
Published in:
Pathology international (2024)
Keyphrases
</>
randomized controlled trial
flow cytometry